Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

y objective was to investigate the effects of oral MTC at 30, 60 and 100 mg doses three times per day, compared with placebo, over 24 weeks on cognitive function as measured by the ADAS-cog in patients with mild or moderate Alzheimer's, stratified by stage of the disease. Another objective was to determine MTC's potential to modify the course of Alzheimer's over 19 months. Imaging results from SPECT and PET scans were collected at baseline and after 24 weeks of treatment.

The researchers found that, at 24 weeks, MTC produced a significant improvement relative to placebo of -5.5 ADAS-cog units in moderate subjects at the 60 mg dose (p = 0.0208). There was no placebo decline in people with mild Alzheimer's in the control group over the first 24 weeks preventing initial efficacy analysis, although efficacy was demonstrated in mild Alzheimer's by SPECT-scan outcomes over the same period. MTC stabilized the progression of Alzheimer's over 50 weeks in both mild and moderate Alzheimer's. The overall effect size was -6.8 ADAS-cog units vs. decline of 7.8 units in the control arm (p < 0.0001), with significant efficacy demonstrated separately in mild and moderate subgroups.

According to the researchers, as a first approximation to supporting disease modifying efficacy, treatment with MTC at the 60mg dose produced a significantly larger effect size at 50 weeks than at 24 weeks implying an effect on the rate of cognitive decline (p = 0.0014). This was confirmed in a mixed effects slope analysis, showing an 81 percent reduction of long run rate of progression of decline over 50 weeks (p < 0.0001). The final 84-week analysis confirmed the long term effect of the 60mg dose in subjects remaining on treatment, with apparent decline still not significantly different from baseline at the final assessment, whereas there was significant decline in the other study arms.

The researchers added that brain imaging using SPECT and PET confirmed the clinical trial results
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SUNNYVALE, Calif. , June 22 Xoft, ... tube technology, today announced the integration of its Axxent® ... a state of the art, fully comprehensive breast center ... of breast cancer. The Pink Lotus Breast Center is ...
... June 22 The SCOOTER Store today announced a major ... the delivery of a power wheelchair to Earvin Thompson of ... assistance from the nation,s leading provider of power mobility equipment, will enjoy ... , , ...
Cached Medicine Technology:Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... the popular Swedish children,s TV show Bolibompa, but ... new study from the University of Gothenburg explores ... as well as the link between young children,s ... Steingerdur Olafsdottir,s doctoral thesis focuses on the presence ... show Bolibompa. Healthy foods dominated in the Swedish-produced ...
(Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
(Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
(Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
Breaking Medicine News(10 mins):Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... Independence Day, NEW YORK, March 28 ... its website Healingstartswithus.net to create a,grassroots online network ... reach 1 million pledges by Independence Day, July ... an overflowing crowd of community,civic, social, political leaders ...
... Conseco, Inc. (NYSE:,CNO) announced today that it has ... ended December 31, 2007 with the Securities and Exchange,Commission., ... for 2007 was $194.0,million, compared to the $210.1 million ... results. The reported net loss applicable to,common stock for ...
... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
... fever, sometimes as high as 104 or 105 degrees, and ... hospital runs test after test, specialists are brought in, but ... one knows how many go through this cyclical nightmare. ... any obvious symptoms and dont respond to antibiotics or fever ...
... stem cells to be engineered into new blood vessels or ... the hair on their patients heads, according to new research ... , Engineering blood vessels for bypass surgery, promoting the ... using stem cells obtained from the most accessible source -- ...
... Pa., March 28 Governor Edward G.,Rendell today released ... which,explains the March 31 deadline for MCare fund assessment ... I wrote informing you that the state was in ... 10 years while providing,access to affordable health care for ...
Cached Medicine News:Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2
Indications For Usage: , ,For use during pulmonary lung function testing...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
Medicine Products: